Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
Recruitment status was Recruiting
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.
Adult Langerhans Cell Histiocytosis
Childhood Langerhans Cell Histiocytosis
Multiple Myeloma and Plasma Cell Neoplasm
Procedure: peripheral blood stem cell transplantation
|Study Design:||Primary Purpose: Treatment|
|Official Title:||The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation|
- Safety [ Designated as safety issue: Yes ]
- Clinical response [ Designated as safety issue: No ]
- Survival rate [ Designated as safety issue: No ]
|Study Start Date:||January 1997|
- Determine the efficacy and safety of allogeneic peripheral blood stem cell transplantation in achieving engraftment in patients with hematologic malignancy.
- Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity, relapse, graft-versus-host disease, and survival of patients treated with this regimen.
OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.
Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months.
PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
|United States, New York|
|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center||Recruiting|
|New York, New York, United States, 10032|
|Contact: Clinical Trials Office - Herbert Irving Comprehensive Cancer C 212-305-8615|
|Study Chair:||David G. Savage, MD||Herbert Irving Comprehensive Cancer Center|